Calpers urges GlaxoSmithKline to cut AIDS drugs prices
Date: 16 Apr 2003
The California Public Employees Retirement System (Calpers), the US's largest pension fund, has urged GlaxoSmithKline to review its policy of charging for AIDS drugs in developing countries.
In a letter to GSK chief executive Jean-Pierre Garnier, Calpers president, Sean Harrigan, said the company faces serious damage to its reputation and its share price because of the controversy surrounding the pricing of Aids treatments.
Calpers praised Glaxo for its existing humanitarian aid programmes, but argued that the nature and scale of the issues would leave the company open to criticism regardless.
Mr Harrigan said: "We request that GSK's corporate responsibility committee imme diately and continually evaluate the company's humanitarian efforts in light of a changing environment, including its response to the Aids epidemic."
Bookmark with:
Del.icio.us |
Digg |
reddit |
Facebook |
StumbleUpon
Comments
You must be logged in to add comments
Special Feature
Social responsibility and finance - on the precipice
In a recent article, the BBC's economics editor Robert Peston highlighted the fact that in 2012 the chances are that the economy - punch drunk as it is from the various flavours of debt crisis it has been pummelled with over the course of the year - will be hit by the collapse of a major bank and / or government.
From the same country
Ethical behaviour tied to better financial returns - 11 Jun 2008
SRI investors support UN business and human rights report - 11 Jun 2008
Business leaders lobby for carbon cuts - 20 Jun 2008
GlaxoSmithKline wins approval for bird flu vaccine - 19 May 2008
Anti-corruption enforcement strengthens but problems remain - 14 May 2008
Other stories about this company
US: GlaxoSmithKline boss promises company has changed after $3bn mis-selling fine - 26 Jul 2012
Drug companies cut vaccine prices in search of a more humane business model - 6 Jun 2011
US: Former GlaxoSmithkline executive charged as law targets individuals - 10 Nov 2010
US: GlaxoSmithKline could face $6bn risk over diabetes drug Avandia - 6 Mar 2010
UK: GlaxoSmithKline targets low cost vaccine for malaria - 21 Jan 2010
Kenya: GlaxoSmithKline agrees HIV royalty-free licensing to get medicines to the poor - 21 Jul 2009
Currently most popular stories
AccountAbility hits back at 'untenable' standards board (14 Jan 2011)
Korea: Workers would not report wrongdoings (17 Nov 2006)
Procter & Gamble most consistent top corporate citizen (20 May 2004)
Arguments against corporate social responsibility - redoubled (26 Oct 2008)
Former Yukos executives to complain to human rights court (22 Mar 2006)



No comments added - be the first!